Needham & Company LLC reiterated their buy rating on shares of Stoke Therapeutics ( NASDAQ:STOK – Get Rating ) in a research report released on Tuesday, Benzinga reports. Needham & Company LLC currently has a $25.00 price objective on the stock. Several other research firms also recently commented on STOK. Credit Suisse Group reduced their price target on shares of Stoke Therapeutics from $32.00 to $28.00 and set an outperform rating on the stock in a research note on Tuesday. Cantor Fitzgerald restated an overweight rating and issued a $20.

https://www.dailypolitical.com/2023/03/08/needham-company-llc-reiterates-buy-rating-for-stoke-therapeutics-nasdaqstok.html

#dailypolitical